| Bid | 0.83 |
| Market Cap | 3.13M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.8 |
| PE Ratio (ttm) | -0.18 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.87 |
| Volume | 7,798 |
| Avg. Volume (20D) | 337,059 |
| Open | 0.83 |
| Previous Close | 0.83 |
| Day's Range | 0.83 - 0.87 |
| 52-Week Range | 0.80 - 7.14 |
| Beta | undefined |
About PCSA
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selectiv...
Analyst Forecast
According to 2 analyst ratings, the average rating for PCSA stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 490.04% from the latest price.
2 years ago · seekingalpha.com
Processa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call TranscriptProcessa Pharmaceuticals, Inc. (NASDAQ:PCSA ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Jim Stanker - CFO David Young - President & CEO Conference Call Particip...
